Image

Word Learning in Deaf Children Using Eye-tracking and Behavioral Measures

Recruiting
18 - 60 years of age
Both
Phase N/A

Powered by AI

Overview

Mutual exclusivity is a word learning constraint in which the learner assumes that a given word refers to only one category of objects. In spoken languages, mutual exclusivity has been demonstrated in monolingual children as young as 17 months and cross-linguistically, while multilingual learners show an attenuated mutual exclusivity bias. Mutual exclusivity has not been robustly demonstrated in deaf children acquiring American Sign Language (ASL). Further, it is unclear if mutual exclusivity applies to those learning both a signed and a spoken language. Like unimodal bilinguals, bimodal bilingual (BiBi) children learn two words for an object, but these words are separated by modality. A BiBi child could therefore assume that all objects have two words (like unimodal bilinguals) or that all objects have one spoken word and one sign (within-modality mutual exclusivity). The goals of the current study are to demonstrate mutual exclusivity in monolingual deaf children acquiring ASL, and to determine if BiBi deaf children utilize mutual exclusivity within each modality.

Description

The investigators will investigate how deaf children prioritize input cues to word meaning when linguistic cues (i.e. mutual exclusivity) and referential gaze are in conflict in a structured word learning task.

Participants: Deaf children (n=40) ages 24-60 months. Investigators will recruit 60 children to allow for 33% attrition. While the inclusion criteria are the same as other studies, here investigators do use spoken language exposure as a grouping variable, as follows: based on responses to the language background questionnaire regarding exposure to spoken English, participants will be grouped according to language use as monolingual ASL or bimodal bilingual (spoken English/ASL). Participants will be identified as bimodal bilingual is 1) the primary caregiver reports spoken English to communicate with their child (either alone or in conjunction with ASL), and 2) the primary caregiver reports that their child's ability to understand spoken English is at least a 3 on a Likert-type scale ranging from 0-5. Parents in this group will complete the short-form English CDI in addition to the ASL language measures.

Procedure: Participants will sit across a table from an experimenter who will present pairs of objects--one familiar, one novel--with one pair in each of nine trials (three per condition). The experimenter will prompt the participant to give them one of the toys, signing "I WANT YOU-GIVE-ME WHAT?" Then the experimenter will provide a cue; the child's selection will be recorded. In the gaze condition, the cue will be a gaze shift to the familiar object. In the mutual exclusivity condition, the cue will be a novel sign. In the conflict condition, both a gaze shift to the familiar object and a novel sign will be used. The trial order and object pair will be pseudo-randomly assigned.

Planned analysis: Investigators will use an omnibus mixed effects binomial model to determine how well condition and language environment predict the likelihood to select the novel object, with item and child as random factors.

Eligibility

Inclusion Criteria:

  • Deaf children ages 18-60 months
  • born severely to profoundly deaf
  • have either deaf or hearing parents
  • communicate using American Sign Language
  • have normal to corrected normal vision

Exclusion Criteria:

  • Deaf children who have not been exposed to American Sign Language

Study details

Deafness

NCT05993832

Boston University Charles River Campus

26 January 2024

Step 1 Get in touch with the nearest study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.